Cancer Diagnostics Market (2033): Early Detection, IVD Testing, Breast Cancer, Cancer Care and Research Institutes & United States Growth Expansion

Cancer Diagnostics Market reached US$ 21.71 billion in 2024 and is expected to reach US$ 42.64 billion by 2033, growing at a CAGR of 8.7% during the forecast period of 2025-2033.

DataM Intelligence has released its latest "Cancer Diagnostics Market Size 2026" report, delivering comprehensive insights into market trends, growth opportunities, competitive dynamics, and regional performance. The report covers market size by value and volume, CAGR forecasts, and emerging opportunities, the report delivers data-driven insights into industry developments, competitive trends, and future market outlook, enabling more effective strategic planning and market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/cancer-diagnostic-market?kb

United States: Recent Industry Developments

✅ July 2026: GRAIL partnered with Priority Health to make its Galleri multi-cancer early detection blood test available to self-insured employer groups in Michigan.

✅ June 2026: Guardant Health received FDA approval for Guardant360 CDx as a companion diagnostic for HERNEXEOS, enabling blood-based identification of HER2-mutant advanced non-small cell lung cancer patients.

✅ May 2026: Guardant Health's Shield blood test received a recommendation from the American Cancer Society in updated colorectal cancer screening guidelines, while its Guardant360 Liquid CDx received FDA approval with an expanded genomic footprint.

✅ April 2026: GRAIL integrated the Galleri multi-cancer early detection test with Epic's EHR platform, enabling participating health systems to order tests and access results through existing clinical workflows.

✅ March 2026: The FDA updated authorized companion diagnostics, including new indications for tests such as Guardant360 CDx and Myriad myChoice CDx across breast and ovarian cancers.

✅ February 2026: Guardant Health reported 39% year-over-year fourth-quarter revenue growth, supported by Oncology and Screening, with approximately 79,000 oncology tests performed during the quarter.

✅ January 2026: GRAIL submitted the final module of its FDA Premarket Approval application for the Galleri multi-cancer early detection test.

Find the right strategic partners to accelerate your business. Get started today:- https://www.datamintelligence.com/partner-identification-enquiry/cancer-diagnostic-market?kb

Top List of Key Player:

F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Siemens Healthcare Private Limited, GE HealthCare, Illumina, Inc., Bio-Rad Laboratories, Inc., Hologic, Inc., Koninklijke Philips N.V., BD, and QIAGEN

Key Industry Developments 2026:

✅ July 2026: Caris Life Sciences launched Caris Detect, a multi-cancer early detection blood test combining ultra-deep whole genome and whole transcriptome sequencing with AI algorithms to identify cancer signals at earlier stages.

✅ June 2026: Roche received U.S. FDA approval for its VENTANA PTEN (SP218) RxDx Assay, the first IHC companion diagnostic approved to identify PTEN protein loss in prostate cancer patients, supporting treatment selection.

✅ June 2026: Photocure completed its US$30.5 million acquisition of Vesica Health, adding the AssureMDx urine-based molecular test for early bladder cancer detection and strengthening its precision diagnostics portfolio.

✅ May 2026: Roche entered a definitive agreement to acquire PathAI to integrate its AI-powered pathology capabilities with Roche's companion diagnostics portfolio and support biomarker development and new diagnostic tools.

✅ April 2026: Roche announced an agreement to acquire SAGA Diagnostics, adding its cancer therapy response monitoring platform to Roche's oncology diagnostics portfolio and strengthening capabilities in molecular monitoring.

✅ February 2026: Guardant Health reported new clinical evidence for Guardant Reveal, highlighting its ability to identify recurrence risk in stage III colon cancer through molecular residual disease testing and support treatment decisions.

✅ January 2026: Guardant Health received U.S. FDA approval for Guardant360 CDx as a companion diagnostic for BRAFTOVI in patients with BRAF V600E-mutant metastatic colorectal cancer, expanding its role in targeted cancer treatment selection.

✅ January 2026: Guardant Health and Merck announced a multi-year collaboration to develop and commercialize companion diagnostics using Guardant's liquid and tissue biopsy technologies across Merck's oncology portfolio.

How Our Market Research Process Works 2026-2033:

The Cancer Diagnostics Market report by DataM Intelligence delivers comprehensive insights backed by extensive primary and secondary research. It analyzes key market trends, competitive dynamics, regulatory developments, technological advancements, emerging innovations, and growth opportunities while highlighting potential challenges and evolving market conditions. The report provides actionable intelligence to support strategic planning and identify future market potential.

Latest M & A/ partnerships in 2026:

• July 2026: Tempus AI agreed to acquire Personalis for $1.5 billion, adding Personalis' NeXT Personal MRD technology to its AI-enabled precision oncology platform.

• July 2026: CareDx completed its acquisition of Naveris, adding the NavDx blood-based MRD test for HPV-associated head and neck and anal cancers; Naveris generated approximately $35 million in 2025 revenue.

• June 2026: Photocure completed its acquisition of Vesica Health for a $30.5 million total transaction value, adding the AssureMDx urine-based molecular test for bladder cancer detection.

• May 2026: Roche agreed to acquire PathAI for $750 million upfront plus up to $300 million in milestone payments, strengthening AI-powered digital pathology and precision cancer diagnostics.

• April 2026: CareDx agreed to acquire Naveris for $160 million upfront plus up to $100 million in revenue-based milestone payments, expanding into specialty oncology and liquid-biopsy MRD testing.

• April 2026: Roche agreed to acquire SAGA Diagnostics through Foundation Medicine for up to $595 million, adding the Pathlight tumor-informed MRD platform based on whole-genome sequencing and digital PCR.

• March 2026: Abbott completed its acquisition of Exact Sciences for approximately $21 billion equity value, adding Cologuard, Oncotype DX, Cancerguard and Oncodetect to Abbott's cancer diagnostics portfolio.

• March 2026: Agilent Technologies agreed to acquire Biocare Medical for $950 million, adding immunohistochemistry, in-situ hybridization and pathology solutions supporting oncology diagnostics.

• January 2026: Inspira Technologies signed a non-binding term sheet to acquire an advanced liquid-biopsy cancer diagnostics business in an all-share transaction valued at 40% of Inspira's fully diluted share capital, alongside a $15 million equity investment at a proposed $180 million pre-money valuation.

Buy Now & Unlock 360° Complete Market Insights: https://www.datamintelligence.com/buy-now-page?report=cancer-diagnostic-market?kb

Japan: Recent Industry Developments

✅ July 2026: Abbott began offering its Cancerguard multi-cancer early detection blood test in Japan, its first international market outside the U.S., analyzing biomarkers associated with more than 50 cancer types and subtypes.

✅ June 2026: Natera's Signatera received PMDA approval for colorectal cancer, becoming Japan's first PMDA-approved molecular residual disease test, with commercial launch planned by year-end subject to reimbursement and pricing.

✅ May 2026: Japan continued advancing cancer screening and precision-diagnostics initiatives, with national discussions focused on improving colorectal cancer screening, dense-breast considerations and diagnostic practices.

✅ April 2026: Japanese cancer diagnostics activity increasingly focused on genomic medicine, digital pathology and biomarker-based diagnosis, reflected in the Japanese Cancer Association's 2026 diagnostic research categories.

✅ March 2026: FUJIREBIO, SRL and Shizuoka Cancer Center received MHLW authorization for the Fujinokuni HOPE Onco Panel, a comprehensive genomic profiling system analyzing 410 cancer-related and drug-metabolizing genes.

✅ February 2026: Japan's MHLW revised reimbursement provisions for cancer genomic profiling, covering qualifying next-generation sequencing-based tests analyzing 100 or more cancer-related genes under specified conditions.

✅ January 2026: Sectra began implementing its first digital pathology project in Japan with Kameda Medical Center, supporting digital workflows aimed at improving cancer diagnostics and reducing time to treatment.

Key Segmentation Plannings (2026):

By Product Type: Consumables, Antibodies, Kits & Reagents, Probes, Others, Instruments, Pathology-based, Tissue Processing Systems, Cell Processors, PCR Instruments, Microarrays, Others, Imaging, CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Others

By Technology: IVD Testing, In Situ Hybridization (ISH), Next-generation Sequencing (NGS), Imaging, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Others

By Cancer Type: Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Others

By End User: Hospitals and Clinics, Diagnostic Laboratories, Cancer Care and Research Institutes, Others

Global Market Growth Regional Analysis:

⇥ North merica (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1 - Market Overview: Provides a comprehensive introduction to the Cancer Diagnostics Market, including key segments by region, product type, and application, along with market size, growth potential, and short- and long-term outlook.

Chapter 2 - Emerging Trends: Highlights the latest industry trends, technological advancements, and innovations driving market transformation.

Chapter 3 - Competitive Landscape: Analyzes the competitive environment, including market share, strategic developments, partnerships, and recent mergers and acquisitions.

Chapter 4 - Leading Company Profiles: Presents detailed profiles of major market participants, covering revenue, product portfolios, operating performance, and recent developments.

Chapters 5 & 6 - Regional and Country Analysis: Delivers in-depth insights into market performance across key regions and countries, highlighting revenue trends, growth opportunities, and market potential.

Chapter 7 - Market Segmentation: Examines the market by type, identifying key segments, growth prospects, and high-opportunity areas.

Chapter 8 - Application Analysis: Explores major application areas, emerging demand trends, and sectors contributing to market expansion.

Chapter 9 - Supply Chain Analysis: Maps the end-to-end industry value chain, providing insights into upstream suppliers, downstream channels, and overall market structure.

Chapter 10 - Key Insights and Strategic Outlook: Summarizes the report with actionable insights, strategic recommendations, and growth opportunities to support future market planning.

Request a Customized Market Report Today:- https://www.datamintelligence.com/customize/cancer-diagnostic-market?kb

Market Drivers

• Higher Cancer Incidence: Growing cancer prevalence increases the need for screening, diagnosis, staging, and treatment monitoring across major cancer types.

• Focus on Early Detection: Greater emphasis on identifying cancer at earlier stages is supporting screening programs and advanced diagnostic testing.

• Advances in Molecular Diagnostics: NGS, biomarker testing, digital pathology, and companion diagnostics are improving tumor characterization and treatment selection.

• Adoption of Liquid Biopsy: Blood-based testing offers minimally invasive options for cancer detection, genomic profiling, treatment response assessment, and recurrence monitoring.

FAQ's

Q1: What is the current market size of the Cancer Diagnostics Market and its future outlook?

Ans: The global Cancer Diagnostics Market reached US$ 21.71 billion in 2024 and is forecast to attain US$ 42.64 billion by 2033

Q2: How fast is the Cancer Diagnostics Market expected to grow during the forecast period?

Ans: The market is projected to expand at a CAGR of 8.7% from 2025 to 2033, reflecting strong growth potential over the forecast period.

Q3: Which region leads the Cancer Diagnostics Market?

Ans: North America accounted for the largest market share in 2025

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.